Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Omnicom Group Inc. (OMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Omnicom Group Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $222.01 (market cap $29.60B), while Omnicom Group Inc. trades at $85.75 (market cap $23.58B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Omnicom Group Inc. pays a 3.72% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | OMC | |
|---|---|---|
Market Cap | $29.60B | $23.58B |
Sector | Health | Media |
52-Week High | $491.22 | $86.22 |
52-Week Low | $205.48 | $67.27 |
Enterprise Value | $27.56B | $31.66B |
Dividend Yield | — | 3.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Omnicom Group (OMC) trades at $85.45, up 0.95% with a bullish technical outlook and strong institutional support. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q4 2025 and Q2 2026 missing expectations. Recent acquisition of Interpublic Group has driven 6.1% organic revenue growth and margin expansion, though 2025 saw a net loss of $54.5 million. Analyst consensus price target stands at $107 with 32% buy ratings.
OMC presents a value opportunity with attractive valuation metrics (P/S 0.97) and 4% dividend yield, supported by post-merger synergies and strong cash flow generation. Key risks include integration challenges from the Interpublic acquisition, competitive pressures in advertising services, and debt levels following the merger. The stock's current price offers 25% upside to consensus targets with institutional accumulation signaling confidence in the growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →
